Müller R T, Schürmann N
Orthopädische Universitäts- und Poliklinik Essen.
Zentralbl Chir. 2001 Jan;126(1):55-61. doi: 10.1055/s-2001-11722.
The diagnosis-related reimbursement for total hip- and knee arthroplasty is often interpreted as a claim for cost reduction and thus influences increasingly the surgeon's choice of treatment. With regard to further planned budget reductions the following questions arise: Remains quality payable? Where are cost savings possible?
Prospective analysis of 21 patients with primary hip- and 26 with knee arthroplasties to identify all cost factors during the hospitalization period including the implantation technique and quality improvement measures.
Expenses of 18,763.26 DM for hip- and 18,649.40 DM for knee implants were covered by the diagnosis-related reimbursement. Compared to cemented implants, the average total costs of cementless prostheses were usually less expensive.
Although the current costs are covered, a further reduction of the diagnosis-related reimbursement may result in a loss of quality. The present cost analysis outlines a guideline for an individual calculation and assessment of possible saving effects.
全髋关节和膝关节置换术的诊断相关报销费用常常被理解为降低成本的要求，因此越来越影响外科医生的治疗选择。鉴于进一步计划削减预算，出现了以下问题：质量是否仍需付费？何处可以节省成本？
对21例初次髋关节置换患者和26例初次膝关节置换患者进行前瞻性分析，以确定住院期间的所有成本因素，包括植入技术和质量改进措施。
诊断相关报销涵盖了髋关节植入物费用18,763.26德国马克和膝关节植入物费用18,649.40德国马克。与骨水泥固定植入物相比，非骨水泥假体的平均总成本通常较低。
尽管目前的成本已得到报销，但诊断相关报销费用的进一步降低可能会导致质量下降。目前的成本分析概述了一个用于个别计算和评估可能节省效果的指导方针。
